Nyxoah SA successfully implants Genio system in first U.S. commercial patients for Obstructive Sleep Apnea treatment after FDA approval. The system delivers bilateral stimulation to the hypoglossal nerve, offering a less invasive alternative to traditional therapies. Nyxoah closely monitors key performance indicators like surgeon training, VAC submissions, prior authorization requests, and accounts opened to measure progress and revenue potential. These metrics reflect the company’s strategic advancement and readiness for sustained revenue generation.

Read more at Nasdaq: Nyxoah Launches Genio System In U.S. With First Commercial Implants For Sleep Apnea